Cao Hui, Tuo Lingling, Tuo Yali, Xia Ziyun, Fu Rong, Liu Yang, Quan Yihong, Liu Jue, Yu Zhihong, Xiang Ming
Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China.
Department of Traditional Chinese Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China.
Front Pharmacol. 2017 Jul 7;8:445. doi: 10.3389/fphar.2017.00445. eCollection 2017.
Dangguiliuhuang decoction (DGLHD) is a traditional Chinese medicine (TCM) formula, which mainly consists of angelica, radix rehmanniae, radix rehmanniae praeparata, scutellaria baicalensis, coptis chinensis, astragalus membranaceus, and golden cypress, and used for the treatment of diabetes and some autoimmune diseases. In this study, we explored the potential mechanism of DGLHD against insulin resistance and fatty liver and . Our data revealed that DGLHD normalized glucose and insulin level, increased the expression of adiponectin, diminished fat accumulation and lipogenesis, and promoted glucose uptake. Metabolomic analysis also demonstrated that DGLHD decreased isoleucine, adenosine, and cholesterol, increased glutamine levels in liver and visceral adipose tissue (VAT) of ob/ob mice. Importantly, DGLHD promoted the shift of pro-inflammatory to anti-inflammatory cytokines, suppressed T lymphocytes proliferation, and enhanced regulatory T cells (Tregs) differentiation. DGLHD also inhibited dendritic cells (DCs) maturation, attenuated DCs-stimulated T cells proliferation and secretion of IL-12p70 cytokine from DCs, and promoted the interaction of DCs with Tregs. Further studies indicated that the changed PI3K/Akt signaling pathway and elevated PPAR-γ expression were not only observed with the ameliorated glucose and lipid metabolism in adipocytes and hepatocytes, but also exhibited in DCs and T cells by DGLHD. Collectively, our results suggest that DGLHD exerts anti-insulin resistant and antisteatotic effects by improving abnormal immune and metabolic homeostasis. And DGLHD may be a novel approach to the treatment of obesity-related insulin resistance and hepatic steatosis.
当归六黄汤(DGLHD)是一种中药配方,主要由当归、生地黄、熟地黄、黄芩、黄连、黄芪和黄柏组成,用于治疗糖尿病和一些自身免疫性疾病。在本研究中,我们探讨了当归六黄汤抗胰岛素抵抗和脂肪肝的潜在机制。我们的数据显示,当归六黄汤使血糖和胰岛素水平正常化,增加脂联素的表达,减少脂肪堆积和脂肪生成,并促进葡萄糖摄取。代谢组学分析还表明,当归六黄汤降低了ob/ob小鼠肝脏和内脏脂肪组织(VAT)中的异亮氨酸、腺苷和胆固醇水平,增加了谷氨酰胺水平。重要的是,当归六黄汤促进促炎细胞因子向抗炎细胞因子的转变,抑制T淋巴细胞增殖,并增强调节性T细胞(Tregs)的分化。当归六黄汤还抑制树突状细胞(DCs)成熟,减弱DCs刺激的T细胞增殖以及DCs分泌IL-12p70细胞因子,并促进DCs与Tregs的相互作用。进一步研究表明,当归六黄汤改善脂肪细胞和肝细胞的葡萄糖和脂质代谢时,不仅观察到PI3K/Akt信号通路的改变和PPAR-γ表达的升高,在DCs和T细胞中也有体现。总体而言,我们的结果表明,当归六黄汤通过改善异常的免疫和代谢稳态发挥抗胰岛素抵抗和抗脂肪变性作用。当归六黄汤可能是治疗肥胖相关胰岛素抵抗和肝脂肪变性的一种新方法。